Usage rates of treatments for cardiovascular prevention in patients with type 2 diabetes mellitus without diagnosis of coronary artery disease

Basit Öğe Kaydı
dc.authorid0000-0002-8687-7238
dc.authorid0000-0001-7493-5165
dc.authorid0000-0003-1648-3206
dc.contributor.authorÖztaş, Dilek
dc.contributor.authorKayhan, Mehmet
dc.contributor.authorBalcıoğlu, Hüseyin
dc.contributor.authorSağlan, Yasemin
dc.contributor.authorSarı, Yunus Emre
dc.contributor.authorBilge, Uğur
dc.date.accessioned2021-06-23T18:51:42Z
dc.date.available2021-06-23T18:51:42Z
dc.date.issued2017
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractAim: The aim of this study is to retrospectively investigate the usage rates of antidiabetic treatments, and statin, aspirin and angiotensin (angiotensin converting enzyme inhibitors and angiotensin receptor blockers) based treatments for cardiovascular prevention in patients with type 2 diabetes mellitus. Material and methods: Drug exemption reports issued during 2015 and 2016 were evaluated from the hospital's digital database. Among these reports, files of patients with the DM diagnosis code (E11-E14) and without any diagnosis that could be associated with major cardiac events were scanned, and approximately 31685 records were obtained. Results: A total of 11942 individuals were selected randomly according to simple random sampling method, and the active ingredients of the drugs listed in the drug exemption reports and used by the selected individuals were investigated. When usage in all groups was investigated, it was found that 21.3% of the patients used statin, 26.08% used ACE-I/ARB, and 9.8% used aspirin. Discussion: In conclusion, the use of multiple treatments such as statins, angiotensinogen-dependent treatments, and aspirin in patients with DM2 is associated with a reduction in all-cause mortality. Secondary prevention, however, depends on the early selection of cases, and the initiation of appropriate preventive treatments; progression of the disease can only be stopped this way. © 2017, Scientific Publishers of India, All rights reserved.en_US
dc.description.urihttps://www.scopus.com/record/display.uri?eid=2-s2.0-85039695538&origin=resultslist&sort=plf-f&src=s&st1=Usage+rates+of+treatments+for+cardiovascular+prevention+in+patients+with+type+2&sid=fee078cc3a301c8ddc9fd48e8616c5fd&sot=b&sdt=b&sl=94&s=TITLE-ABS-KEY%28Usage+rates+of+treatments+for+cardiovascular+prevention+in+patients+with+type+2%29&relpos=6&citeCnt=0&searchTerm=&featureToggles=FEATURE_NEW_DOC_DETAILS_EXPORT:1
dc.identifier.endpage8744en_US
dc.identifier.issn0970-938X
dc.identifier.issue20en_US
dc.identifier.scopus2-s2.0-85039695538en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage8737en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12491/3951
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85039695538&partnerID=40&md5=f2a73941abfb48dfa1b367020e354cae
dc.identifier.volume28en_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorKayhan, Mehmet
dc.language.isoenen_US
dc.publisherScientific Publishers of Indiaen_US
dc.relation.ispartofBiomedical Research (India)en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCardiovascular preventionen_US
dc.subjectDiabetes mellitusen_US
dc.titleUsage rates of treatments for cardiovascular prevention in patients with type 2 diabetes mellitus without diagnosis of coronary artery diseaseen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu